Ovid Therapeutics Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Ovid Therapeutics Inc. (OVID) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $223.65 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2022-08-09
- 2022-06-30: Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month $223.65K.
- 2021-06-30: Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month |
|---|---|
| 2022-06-30 | $223.65K 10-Q · filed 2022-08-09 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |